文献速递眼底病与葡萄膜炎

0.19毫克氟轻松玻璃体内植入剂可减轻糖尿病黄斑水肿的治疗负担

The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
PubMed 文献 · Am J Ophthalmol · 2022-10-09

这项多中心36个月4期开放标签观察性研究分析了202只眼(159例患者),评估0.19毫克氟轻松玻璃体内植入剂(ILUVIEN)对糖尿病黄斑水肿治疗负担的影响。结果显示年均治疗次数从植入前的3.5次降至植入后的1.7次,36个月时68.3%患者每年仅需0至2次治疗,最佳矫正视力平均提高4.5个字母(植入前36个月下降6.4个字母),作者认为该植入剂与视力结局改善及治疗负担显著降低相关。

要点

  • 36个月内年均治疗次数从植入前3.5次降至植入后1.7次,36个月时68.3%患者每年需0至2次治疗。
  • 36个月内25%的植入眼无需补充治疗。
  • 36个月时最佳矫正视力平均提高4.5个字母,而植入前36个月下降6.4个字母。

核心结论

  • 在36个月观察期内,0.19毫克氟轻松玻璃体内植入剂与糖尿病黄斑水肿患者视力结局改善及年均治疗负担显著降低相关。

研究设计与样本

  • 多中心、36个月、4期、开放标签观察性研究,对治疗负担数据进行前瞻性和回顾性分析。
  • 纳入既往接受过皮质类固醇治疗且眼压无临床显著升高的糖尿病黄斑水肿患者,共159例患者202只眼,患者未随机化。

主要发现

  • 36个月内年均治疗次数从植入前3.5次降至植入后1.7次,36个月时68.3%患者每年需要0至2次治疗。
  • 植入后需要补充治疗的眼百分比相比植入前下降(每项比较P<.0001)。
  • 36个月内25%的植入眼无需补充治疗。
  • 36个月时最佳矫正视力平均提高4.5个字母,而植入前36个月下降6.4个字母。
  • 眼压>25毫米汞柱发生于植入后未接受补充治疗的18.2%的眼,而接受补充治疗(包括额外眼内类固醇)的眼为27.2%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess treatment burden in patients with diabetic macular edema (DME) after the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN). DESIGN: Prospective and retrospective analyses of a 36-month, phase 4, open-label, observational study. METHODS: Setting: Multicenter. PATIENT POPULATION: Included patients had DME and previously received corticosteroid treatment without a clinically significant rise in intraocular pressure (IOP) (N = 202 eyes in 159 patients). Patients were not randomized. OBSERVATION PROCEDURES: Prospective, observational treatment burden data were analyzed for their relationship to safety and functional efficacy outcomes across 36 months. MAIN OUTCOME MEASURES: Outcomes included the mean number of yearly treatments, supplemental-free probability over time, best-corrected visual acuity, and monitoring of IOP-related events. RESULTS: Over 36 months, the mean number of yearly treatments decreased from 3.5 before FAc to 1.7 after FAc; at 36 months, 68.3% of patients required 0 to 2 treatments per year. After FAc, the percentage of eyes requiring supplemental therapy decreased vs before FAc (P < .0001 for each). Through 36 months, 25% of FAc-treated eyes did not require supplemental treatment. At 36 months, mean best-corrected visual acuity increased by 4.5 letters vs a decline of 6.4 letters in the 36 months before FAc. IOP elevations >25 mm Hg occurred in 18.2% of eyes that did not receive supplemental treatment after FAc vs 27.2% of eyes that received supplemental treatments, which included additional intraocular steroids. CONCLUSIONS: Over 36 months, the FAc implant is associated with improved visual outcomes and better disease control as measured by a significant reduction in yearly treatment burden in patients with DME.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Merrill PT, Holekamp N, Roth D, et al. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema. Am J Ophthalmol. 2022. PMID: 36223849. doi:10.1016/j.ajo.2022.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。